Week 1 - Clinical Judgment and Safety Flashcards
List three most important properties of drugs. Which is the most important?
Effectiveness, safety, selectivity.
Effectiveness most important.
What does selectivity mean?
Produces only desired responses for which it is given.
List three types of drug names. Which is the best for communicating between health professionals?
Chemical, generic, trade
Generic name is the best.
What factor primarily determines the drug concentration at the receptor?
Administration.
Pharmacokinetics determines what?
How much of a drug reaches the sites of action
List four processes of pharmacokinetics.
Absorption, distribution, metabolism, excretion`
How does changing the route from intravenous to oral influence dosage?
Oral dosages are usually higher than intravenous dosages, because there is a barrier to absorption.
Pharmacodynamics refers to what action?
The nature and intensity of response at its site of action.
Name the six rights of safe medication administration.
Right patient, right drug, right dose, right route, right time, right documentation
Explain the difference between a contraindication and precaution.
A contraindication prevents the drug use under all but the most severe circumstances. A precaution increases the likelihood of an adverse reaction, but not a life–threatening one.
The Federal Food, Drug, and Cosmetic Act of 1938 resulted in what mandate?
Testing for toxicity
The Harris-Kefauver Amendment of 1962 mandated what two requirements?
Proof of effectiveness and rigorous testing procedures.
The Controlled Substances Act of 1970 identified drugs with a potential for what? What was developed?
Potential for abuse.
Developed Schedules I – V
Schedule I includes what types of drugs? Schedule II?
Schedule I- Drugs with no acceptable medical use and high abuse potential.
Schedule II- Drugs with therapeutic use, but high abuse potential.
THE FDA Amendments Act (FDAAA) of 2007 allowed the FDA oversight over what?
Safety oversight over drugs that had been approved. Specifically gave the FDA the authority to require postmarketing safety studies, labeling changes to include new safety information, and restricting the distribution of drugs with safety concerns.